持续皮下输注磷左旋多巴-磷卡比多巴治疗晚期帕金森病患者的疗效与安全性:一项随机、双盲、活性对照3期试验
这项12周随机双盲活性对照3期试验在美国和澳大利亚65个中心纳入141例晚期帕金森病患者,比较持续皮下输注磷左旋多巴-磷卡比多巴与口服左旋多巴-卡比多巴的疗效与安全性。结果显示,磷左旋多巴-磷卡比多巴组在无困扰性运动障碍的“开”期时间和“关”期时间改善上均显著优于口服左旋多巴-卡比多巴组。作者认为该方案具有有利的获益-风险特征,可能成为晚期帕金森病患者的非手术替代选择。
要点
- 磷左旋多巴-磷卡比多巴组无困扰性运动障碍的“开”期时间较基线增加2.72小时,口服左旋多巴-卡比多巴组增加0.97小时,组间差异1.75小时(95%CI 0.46-3.05;p=0.0083)。
- 磷左旋多巴-磷卡比多巴组“关”期时间较基线减少2.75小时,口服左旋多巴-卡比多巴组减少0.96小时,组间差异-1.79小时(95%CI -3.03至-0.54;p=0.0054)。
- 磷左旋多巴-磷卡比多巴组不良事件发生率为85%(63/74),口服左旋多巴-卡比多巴组为63%(42/67);严重不良事件发生率分别为8%(6/74)和6%(4/67)。
核心结论
- 磷左旋多巴-磷卡比多巴改善了运动波动,在无困扰性运动障碍的“开”期时间和“关”期时间两方面均带来获益。
- 磷左旋多巴-磷卡比多巴具有有利的获益-风险特征,可能成为晚期帕金森病患者的非手术替代选择。
研究设计与样本
- 一项为期12周的随机、双盲、双模拟、活性对照研究,在美国和澳大利亚65个学术和社区研究中心进行。
- 研究纳入对左旋多巴反应良好但当前治疗控制不佳的晚期帕金森病患者,包括平均每日“关”期时间至少2.5小时。
- 患者按1:1随机分配至持续皮下输注磷左旋多巴-磷卡比多巴加口服安慰剂组,或口服速释左旋多巴-卡比多巴加持续皮下输注安慰剂溶液组。
- 随机化按研究中心分层,采用区组大小为2的置换区组方案;受试者、研究者、研究中心人员和申办方对治疗分组设盲。
- 主要终点和第一个关键次要终点分别为第12周时无困扰性运动障碍的“开”期时间和“关”期时间较基线的变化,均采用意向性治疗分析,应用重复测量混合模型评估。
主要发现
- 2020年10月19日至2021年9月29日期间,筛选270例参与者,入组174例,其中141例被随机分配并接受治疗:磷左旋多巴-磷卡比多巴加口服安慰剂胶囊组74例,口服速释左旋多巴-卡比多巴胶囊加持续皮下输注安慰剂溶液组67例。
- 与左旋多巴-卡比多巴相比,磷左旋多巴-磷卡比多巴组无困扰性运动障碍的“开”期时间增加更显著(模型估计均值[SE] 2.72[0.52]小时 vs 0.97[0.50]小时;差异1.75小时,95%CI 0.46至3.05;p=0.0083)。
- 与左旋多巴-卡比多巴相比,磷左旋多巴-磷卡比多巴组“关”期时间减少更显著(-2.75[0.50]小时 vs -0.96[0.49]小时;差异-1.79小时,95%CI -3.03至-0.54;p=0.0054)。
- 磷左旋多巴-磷卡比多巴组74例中63例(85%)报告不良事件,左旋多巴-卡比多巴组67例中42例(63%)报告不良事件;严重不良事件发生率两组相似(分别为6/74[8%] vs 4/67[6%])。
- 磷左旋多巴-磷卡比多巴组最常见的不良事件为输注部位不良事件(红斑20例[27%]、疼痛19例[26%]、蜂窝织炎14例[19%]、水肿9例[12%]),大多为非严重且轻至中度。
临床怎么用
- 作者认为,磷左旋多巴-磷卡比多巴改善了运动波动,具有有利的获益-风险特征,可能成为晚期帕金森病患者的非手术替代选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Levodopa is the most effective symptomatic therapy for Parkinson's disease, but patients with advanced Parkinson's disease develop motor fluctuations with chronic oral levodopa therapy. Foslevodopa-foscarbidopa is a soluble formulation of levodopa and carbidopa prodrugs that is delivered as a 24-h/day continuous subcutaneous infusion, and we aimed to assess the safety and efficacy of this formulation in patients with advanced Parkinson's disease. METHODS: A 12-week randomised, double-blind, double-dummy, active-controlled study was done at 65 academic and community study centres in the USA and Australia. Patients with levodopa-responsive advanced Parkinson's disease inadequately controlled on current therapy, including at least 2·5 h of average daily off time, were randomly assigned (1:1) to continuous subcutaneous infusion of foslevodopa-foscarbidopa plus oral placebo or to oral immediate-release levodopa-carbidopa plus continuous subcutaneous infusion of placebo solution. Randomisation was stratified by site by means of a permutated-block schedule with a block size of two. The participants, treating investigators, study site personnel, and sponsor were masked to treatment group allocation. The primary and first key secondary endpoint in the hierarchical testing strategy were change from baseline to week 12 in on time without troublesome dyskinesia and off time, respectively; both endpoints were evaluated by an intention-to-treat analysis applying a mixed model for repeated measures analysis. Safety and tolerability were assessed throughout the study. The study is completed and is listed on ClinicalTrials.gov, NCT04380142. FINDINGS: Between Oct 19, 2020, and Sept 29, 2021, of 270 participants screened and 174 enrolled, 141 were randomly assigned and received continuous subcutaneous infusion of foslevodopa-foscarbidopa plus oral placebo capsules (n=74) or oral encapsulated immediate-release levodopa-carbidopa plus continuous subcutaneous infusion of placebo solution (n=67). Compared with levodopa-carbidopa, foslevodopa-foscarbidopa showed a significantly greater increase in on time without troublesome dyskinesia (model-based mean [SE] 2·72 [0·52] vs 0·97 [0·50] h; difference 1·75 h, 95% CI 0·46 to 3·05; p=0·0083) and a significantly greater reduction in off time (-2·75 [0·50] vs -0·96 [0·49] h; difference -1·79 h, -3·03 to -0·54; p=0·0054). Hierarchical testing ended after the first secondary endpoint. Adverse events were reported in 63 (85%) of 74 patients in the foslevodopa-foscarbidopa group versus 42 (63%) of 67 in the levodopa-carbidopa group, and incidences of serious adverse events were similar between the groups (six [8%] of 74 vs four [6%] of 67, respectively). The most frequent adverse events in the foslevodopa-foscarbidopa group were infusion site adverse events (erythema 20 [27%]), pain 19 [26%]), cellulitis (14 [19%]), and oedema (nine [12%]), most of which were non-serious and mild-moderate in severity. The only system organ class that had more than one serious adverse event in the foslevodopa-foscarbidopa group was infections and infestations (catheter site cellulitis [one [1%]] and infusion site cellulitis [one [1%]). Adverse events led to premature discontinuation of study drug in 16 (22%) of 74 participants in the foslevodopa-foscarbidopa group versus one (1%) of 67 participants in the oral levodopa-carbidopa group. INTERPRETATION: Foslevodopa-foscarbidopa improved motor fluctuations, with benefits in both on time without troublesome dyskinesia and off time. Foslevodopa-foscarbidopa has a favourable benefit-risk profile and represents a potential non-surgical alternative for patients with advanced Parkinson's disease. FUNDING: AbbVie.
引用
- Soileau MJ, Aldred J, Budur K, et al. Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial. Lancet Neurol. 2022. PMID: 36402160. doi:10.1016/S1474-4422(22)00400-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。